Cite
HARVARD Citation
Blauvelt, A. et al. (2021). Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British journal of dermatology. pp. 640-651. [Online].